Changes in Pulmonary Circulation in Experimental Model of Pulmonary Thromboembolism after Carvedilol Treatment
- 4 Downloads
In experiments on isolated perfused rabbit lungs, we studied changes in the pulmonary microcirculation in response to carvedilol injection and after modelling pulmonary thromboembolism under conditions of α1- and β1,2-adrenoceptor blockade with this drug. Carvedilol had mainly vasodilator effects on the pulmonary arterial vessels; the pulmonary venous resistance increased and the capillary filtration coefficient remained unchanged under these conditions. In case of pulmonary thromboembolism against the background of carvedilol treatment, the increase in precapillary resistance and the capillary filtration coefficient was more pronounced that in the control, but the postcapillary resistance increased to a lesser extent. The increase in the capillary filtration coefficient is a result of elevated precapillary resistance and enhanced endothelial permeability.
Key Wordscarvedilol isolated lungs pulmonary thromboembolism capillary filtration coefficient pulmonary veins
Unable to display preview. Download preview PDF.
- 2.Minushkina L. Carvedilol in clinical practice. Vrach. 2009;(11):65-69. Russian.Google Scholar
- 3.Chazova IЕ, Irodova NL, Krasnikova TL, Arefyeva TI, Lazutkina VK, Orlova YaA, Sokolov SF, Ataullakhanova DM, Masenko VP, Konovatova GG, Lankin VZ. Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy. Ter. Arkh. 2005;77(4):66-72. Russian.Google Scholar
- 4.Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, Voelkel NF. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am. J. Respir. Crit. Care Med. 2010;182(5):652-660.CrossRefGoogle Scholar
- 5.Chen Q, Yi B, Ma J, Ning J, Wu L, Ma D, Lu K, Gu J. α2-adrenoreceptor modulated FAK pathway induced by dexmedetomidine attenuates pulmonary microvascular hyper-permeability following kidney injury. Oncotarget. 2016;7(35):55 990-56 001.Google Scholar
- 6.Drake JI, Gomez-Arroyo J, Dumur CI, Kraskauskas D, Natarajan R, Bogaard HJ, Fawcett P, Voelkel NF. Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiol. Genomics. 2013;45(12):449-461.CrossRefGoogle Scholar
- 7.Fujio H, Nakamura K, Matsubara H, Kusano KF, Miyaji K, Nagase S, Ikeda T, Ogawa A, Ohta-Ogo K, Miura D, Miura A, Miyazaki M, Date H, Ohe T. Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. J. Cardiovasc. Pharmacol. 2006;47(2):250-255.CrossRefGoogle Scholar
- 9.Gomez O, Okumura K, Honjo O, Sun M, Ishii R, Bijnens B, Friedberg MK. Heart rate reduction improves biventricular function and interactions in experimental pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol. 2018;314(3):H542-H551.Google Scholar